fig6

From: Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin

Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin

Figure 6. B. fragilis NCTC 9343 supernatant harvested during growth (0-36 h) could significantly (^***P < 0.001) stimulate more LDH release, measured by OD₄₉₀, from MCF-7 (HR[+]/HER2[-]) breast cancer cells in vitro compared to BHI control (A). However, this was not reflected as cell death since viability measured by OD₄₉₀ (B) was not significantly different than BHI (^*P < 0.05). Linear regression analysis showed that this was a dose dependent relationship (slope = 0.0186, P-value = 4.52 × 10^-8%) (C). All conditions had n = 16, OD490 readings are corrected for background noise i.e., BHI media. Welch’s two sample t-test was used to compare the means of BHI and B. fragilis for both (A) and (B). LDH: Lactate dehydrogenase; BHI: brain-heart infusion.